Search

everythinglearnresearchcommunity

for

Search:↓

A 42-year-old user shared progress after 6 months using 1.25mg finasteride and 5mg oral minoxidil daily, with 5% topical minoxidil twice a day, improved nutrition, and weekly dermarolling. The user noticed some shedding and slower regrowth but remains disciplined, while others commented on the impressive results and potential side effects of high minoxidil doses.

A user started working with a leading hair cloning lab to address their hair loss. They have a computer science background and will assist with data science.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

A 37-year-old male started a hair loss treatment 7 weeks ago using 1mg finasteride, 1.5mg minoxidil, and microneedling, with noticeable coverage improvement except for the right temple. He is considering a hair transplant in the future if needed.

A user shared progress pictures after 5 months of using 1mg finasteride daily, 1ml minoxidil topically every night, and 1.5mm microneedling weekly. Responses included skepticism and congratulations.

A new hair loss treatment using dermal exosomes can restore up to 90% of lost hair in mice. Users discuss potential human trials and compare it to Minoxidil and Finasteride.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

User started hair loss treatment 6 months ago using 0.5mg dutasteride, 5mg oral minoxidil, 80mg RU58841, and microneedling 1.5mm every other week. They experienced significant hair regrowth and no side effects, with others encouraging continued progress.

A user (Majestic-Head3874) who has had successful hair regrowth with the combination of topical minoxidil, oral finasteride and microneedling treatments. People are asking for details about these treatments and Majestic-Head3874 is sharing the regimen they used.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The user has been using Rogaine (minoxidil), dermastamping, Nizoral shampoo, and spironolactone for 6 months with minimal visible results. They are advised to consider finasteride and be cautious with microneedling frequency and depth.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

A user's 6 month hairline results from using dutasteride and microneedling, which resulted in successful regrowth of their thinning temples. Other users commented with similar experiences that were also achieved through the use of finasteride, dutasteride and minoxidil.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.